BACKGROUND: Low serum testosterone is a common condition in aging associated with decreased muscle mass and insulin resistance. This study evaluated whether low testosterone levels are a risk factor for mortality in male veterans. METHODS: We used a clinical database to identify men older than 40 years with repeated testosterone levels obtained from October 1, 1994, to December 31, 1999, and without diagnosed prostate cancer. A low testosterone level was a total testosterone level of less than 250 ng/dL (<8.7 nmol/L) or a free testosterone level of less than 0.75 ng/dL (<0.03 nmol/L). Men were classified as having a low testosterone level (166 [19.3%]), an equivocal testosterone level (equal number of low and normal levels) (240 [28.0%]), or a normal testosterone level (452 [52.7%]). The risk for all-cause mortality was estimated using Cox proportional hazards regression models, adjusting for demographic and clinical covariates over a follow-up of up to 8 years. RESULTS: Mortality in men with normal testosterone levels was 20.1% (95% confidence interval [CI], 16.2%-24.1%) vs 24.6% (95% CI, 19.2%-30.0%) in men with equivocal testosterone levels and 34.9% (95% CI, 28.5%-41.4%) in men with low testosterone levels. After adjusting for age, medical morbidity, and other clinical covariates, low testosterone levels continued to be associated with increased mortality (hazard ratio, 1.88; 95% CI, 1.34-2.63; P<.001) while equivocal testosterone levels were not significantly different from normal testosterone levels (hazard ratio, 1.38; 95% CI, 0.99%-1.92%; P=.06). In a sensitivity analysis, men who died within the first year (50 [5.8%]) were excluded to minimize the effect of acute illness, and low testosterone levels continued to be associated with elevated mortality. CONCLUSIONS: Low testosterone levels were associated with increased mortality in male veterans. Further prospective studies are needed to examine the association between low testosterone levels and mortality.
BACKGROUND: Low serum testosterone is a common condition in aging associated with decreased muscle mass and insulin resistance. This study evaluated whether low testosterone levels are a risk factor for mortality in male veterans. METHODS: We used a clinical database to identify men older than 40 years with repeated testosterone levels obtained from October 1, 1994, to December 31, 1999, and without diagnosed prostate cancer. A low testosterone level was a total testosterone level of less than 250 ng/dL (<8.7 nmol/L) or a free testosterone level of less than 0.75 ng/dL (<0.03 nmol/L). Men were classified as having a low testosterone level (166 [19.3%]), an equivocal testosterone level (equal number of low and normal levels) (240 [28.0%]), or a normal testosterone level (452 [52.7%]). The risk for all-cause mortality was estimated using Cox proportional hazards regression models, adjusting for demographic and clinical covariates over a follow-up of up to 8 years. RESULTS: Mortality in men with normal testosterone levels was 20.1% (95% confidence interval [CI], 16.2%-24.1%) vs 24.6% (95% CI, 19.2%-30.0%) in men with equivocal testosterone levels and 34.9% (95% CI, 28.5%-41.4%) in men with low testosterone levels. After adjusting for age, medical morbidity, and other clinical covariates, low testosterone levels continued to be associated with increased mortality (hazard ratio, 1.88; 95% CI, 1.34-2.63; P<.001) while equivocal testosterone levels were not significantly different from normal testosterone levels (hazard ratio, 1.38; 95% CI, 0.99%-1.92%; P=.06). In a sensitivity analysis, men who died within the first year (50 [5.8%]) were excluded to minimize the effect of acute illness, and low testosterone levels continued to be associated with elevated mortality. CONCLUSIONS: Low testosterone levels were associated with increased mortality in male veterans. Further prospective studies are needed to examine the association between low testosterone levels and mortality.
Authors: Giovanni Corona; Giulia Rastrelli; Linda Vignozzi; Edoardo Mannucci; Mario Maggi Journal: Asian J Androl Date: 2012-01-30 Impact factor: 3.285
Authors: Juraj Fillo; Jan Breza; Michaela Levčíkova; Jan Luha; Anna Vachulova; Štefan Durdík; Peter Labaš Journal: Int Urol Nephrol Date: 2012-08 Impact factor: 2.370
Authors: Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh Journal: Endocr Rev Date: 2017-06-01 Impact factor: 19.871
Authors: Marcello Maggio; Fulvio Lauretani; Gian Paolo Ceda; Stefania Bandinelli; Shari M Ling; E Jeffrey Metter; Andrea Artoni; Laura Carassale; Anna Cazzato; Graziano Ceresini; Jack M Guralnik; Shehzad Basaria; Giorgio Valenti; Luigi Ferrucci Journal: Arch Intern Med Date: 2007-11-12
Authors: Juan Jesús Carrero; Abdul Rashid Qureshi; Paolo Parini; Stefan Arver; Bengt Lindholm; Peter Bárány; Olof Heimbürger; Peter Stenvinkel Journal: J Am Soc Nephrol Date: 2009-01-14 Impact factor: 10.121
Authors: Andy Menke; Eliseo Guallar; Sabine Rohrmann; William G Nelson; Nader Rifai; Norma Kanarek; Manning Feinleib; Erin D Michos; Adrian Dobs; Elizabeth A Platz Journal: Am J Epidemiol Date: 2010-01-18 Impact factor: 4.897